Moreover, the beneficial effects of AT1 receptor blockers on adipose tissue mass and insulin resistance in obesity could be related to the enhancement of adiponectin expression, the reduction of leptin expression, and the concomitant correction of the leptin/adiponectin imbalance [20]. Here, ADIPOQ is linked to Insulin resistance.